Incidence of Sepsis After Craniocerebral Operation
The Incidence and Outcome of Sepsis After Craniocerebral Operation
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
This is a prospective cohort study aiming to describe the incidence and outcome of sepsis in critical patients undergoing craniotomy. This study has been approved by the institutional review board of Beijing Tiantan hospital, and the need for informed consent was waived.
All patients over 18 years of age in intensive care will be screened for sepsis at admission or during their ICU stay, whereas those who stay in the ICU for <24 hrs for routine postoperative surveillance will be excluded. Patients readmitted into ICU and have been included at their first admission will not be included for a second time. Each center has one or more investigators who are residents of intensive care medicine and responsible for screening, patient records, and follow-up. They all have received at least one year of clinical training in critical care medicine and had previous research experience.
Sepsis and septic shock are diagnosed according to the sepsis 3.0 criteria. Acute organ dysfunction is defined as a Sequential Organ Failure Assessment (SOFA) score of 2 for the organ in question. The causal relationship between sepsis and organ dysfunction is confirmed based on medical recording and communication between the investigators and related ICU physicians. Infection is defined by the attending physicians as the presence of polymorphonuclear cells in a normally sterile body fluid(except blood),positive culture or Gram stain of a normally sterile body fluid or tissue, unquestionable clinical signs of infection, such as fecal peritonitis, necrotizing fasciitis, wound with purulent discharge, et al, or clinical suspected infection with corresponding antibiotic treatment. ICU-acquired infection is defined as infection identified 48 hours after ICU admission. Antibiotic consociation application is defined as the daily administration of more than one kind of the following antibiotics: penicillins, cephalosporins, carbapenem, macrolides, glycopeptides, aminoglycosides, quinolones, sulfonamides, and other antibiotics.
For patients developing sepsis at ICU admission or during their ICU stay, the following data will be collected using preprinted case report forms: age, sex, primary diagnosis, chronic comorbidities, clinical and laboratory data for admission Acute Physiology and Chronic Health Evaluation (APACHE) II and SOFA score, clinical and laboratory data for maximum SOFA score, microbiological and clinical infectious information, occurrence of ICU-acquired infection, antibiotics administered, hospital length of stay (LOS), ICU LOS, hospital costs, and outcome. For patients who have not developed severe sepsis at ICU admission or during the ICU stay, only age, sex, primary diagnosis, chronic comorbidities, ICU LOS, and outcome will be recorded. If a patient has more than one episode that meet the criteria, only the data from the first episode will be included in the study.
All recorded data will be screened in details by medical personnel for any missing information, logical errors, or insufficient details.
Continuous variables were expressed as mean (SD) and analyzed by unpaired Student's t test. Nonparametric variables were expressed as median and 25-75% percentiles and analyzed by the Mann-Whitney test. Categorical variables were expressed as absolute (n) and relative (%) frequency and were analyzed by chi-square test, as appropriate. p < 0.05 was considered statistically significant for all comparisons. SPSS version 19.0 for windows software was used for the statistical analysis.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100050
- Beijing Tian tan Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- 18 years or older
- ICU length of stay ≥ 24 hours
- after craniotomy
Exclusion Criteria:
- <18 years
- ICU length of stay < 24 hours
- Patients or their immediate family members refuse to participate in the research
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
sepsis group
Patients have developed sepsis at ICU admission or during their ICU stay.
|
|
non-sepsis group
Patients do not develope sepsis at ICU admission or during their ICU stay.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of sepsis
Time Frame: 28 days
|
The incidence of sepsis in critical patients undergoing craniotomy
|
28 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Jian-Xin Zhou, MD, Beijing Tiantan Hospital, Capital Medical Universtity
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- JZhou
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sepsis
-
NCT06809868RecruitingSepsis | Sepsis, Severe | Sepsis and Septic Shock | Sepsis at Intensive Care Unit | Sepsis, Septic Shock | Sepsis, Severe Sepsis and Septic Shock | Sepsis With Multiple Organ Dysfunction (MOD) | Sepsis With Acute Organ Dysfunction
-
NCT07497139Not yet recruitingSepsis Induced Myocardial Dysfunction | Sepsis Induced Cardiomyopathy
-
NCT04979767RecruitingSepsis | Septic Shock | Sepsis Syndrome | Sepsis, Severe | Sepsis Bacterial | Sepsis Bacteremia
-
NCT05763680RecruitingMicrobial Colonization | Neonatal Infection | Neonatal Sepsis, Early-Onset | Microbial Disease | Clinical Sepsis | Culture Negative Neonatal Sepsis | Neonatal Sepsis, Late-Onset | Culture Positive Neonatal Sepsis
-
NCT03249597CompletedSepsis | Sepsis Syndrome | Sepsis, Severe
-
NCT02232750CompletedSepsis, Severe Sepsis and Septic Shock
-
NCT02135770CompletedSevere Sepsis With Septic Shock | Severe Sepsis Without Septic Shock
-
NCT03037281CompletedSepsis | Septic Shock | Severe Sepsis | Sepsis Syndrome
-
NCT05304728Enrolling by invitationSevere Sepsis | Severe Sepsis Without Septic Shock